Skip to content

The efficacy and safety of pulvinar stimulation in the treatment of refractory posterior cortex epilepsy

The efficacy and safety of pulvinar stimulation in the treatment of refractory posterior cortex epilepsy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046414
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-05-17
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Experimental group:pulvinar stimulation on
Control group:pulvinar stimulation off

Sponsors

Xuanwu Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14 to 65 years; 2. Diagnosed as refractory epilepsy.(resistant to AED medication for at least 2 years); and considering as the posterior cortex epilepsy after comprehensive presurgical evaluation. 3. With difficulty in the removal of epileptic tissue, or refusal of resection surgery; 4. At least 4 seizures per month; 5. Agree to participate in this study and signed on the informed consent; 6. Comply with the protocol of this study and agree on the follow-up examination as request.

Exclusion criteria

Exclusion criteria: 1. Suffer from brain tumors or other degenerative diseases of the central nervous system; 2. Existing mental illness; 3. There are structural changes in the thalamus occipital; 4. Severe cognitive dysfunction, IQ<55; 5. Comprehensive or special types of hereditary epilepsy; 6. Pregnant women may have a high risk of bleeding; 7. Other serious physical diseases or severe abnormal liver and kidney function in laboratory tests; 8. Patients who cannot complete the electrical stimulation test due to objective factors; 9. Abnormal laboratory examinations during the screening period, or other abnormal laboratory examinations considered to be clinically important.

Design outcomes

Primary

MeasureTime frame
The frequency and severity of seizures;

Secondary

MeasureTime frame
The patient's quality of life (QOLIE-31 scale);The score of anxiety scale (GAD-7) and depression scale (NDDI-E);

Countries

China

Contacts

Public ContactRen Liankun

Xuanwu Hospital, Capital Medical University

rlkbrain2000@yahoo.com+86 13681576621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026